Skip to content
value.today

Neurotrope, Inc.

🇺🇸 Plantation, Florida, USABiotechnologyFounded 2011
Total raised
$40 M
2 rounds on record
Latest round
$25 M
Nov 2016
First round on record
Nov 2015
Today
Private
No later event on record

Funding rounds

2 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Neurotrope, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Nov 2016$25 MNo. 2$10 to $50 million

Neurotrope, Inc.: Raise no. 2, Nov 2016

Investors in this round

221 investors had bought by the notice of Dec 1, 2016: 221 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 3 investors are named for Neurotrope, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$25 M of $25 M offered
Smallest investment taken
no minimum stated
What was sold
equity, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$2,450,597
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Nevada

People named in the notice

  • Dan Alkon · Executive Officer
  • Robert Weinstein · Executive Officer
  • Susanne Wilke · Executive Officer, Director
  • Bruce Bernstein · Director
  • James Gottlieb · Director
  • Joshua Silverman · Director
  • Kenneth Gorelick · Director
  • Shana Phares · Director
  • William Singer · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Katalyst Securities LLC (CRD 112494) · Astoria, New YorkSold in AK, AZ, CA, CO, CT, FL, GA, IA, IL, IN, KS, MA, MD, MI, MN, NC, NH, NJ, NV, NY, OH, OK, PA, RI, TX, UT, WA, WI
  • GP Nurmenkari Inc. (CRD 153480) · New York, New YorkSold in CT, FL, IL, MD, NY

Remarks in the notice

  • On fees: “The two placement agents also received warrants to purchase stock.”

Signed by Robert Weinstein, CFO, Executive VP, Secretary and Treasurer. Source: SEC Form D, newest notice filed Dec 1, 2016. Read the notice at the SEC.

equitySEC
Nov 2015$15 MNo. 1$10 to $50 million

Neurotrope, Inc.: Raise no. 1, Nov 2015

Investors in this round

136 investors had bought by the notice of Nov 24, 2015: 136 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 3 investors are named for Neurotrope, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$15 M of $20 M offered; $5 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$1,532,992
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions as estimates
The company
Corporation, incorporated in Nevada

People named in the notice

  • Charles S. Ramat · Executive Officer, Director
  • Robert S. Weinstein · Executive Officer
  • James E. Gottlieb · Director
  • Jay M. Haft · Director
  • Larry D. Altstiel, MD · Director
  • Paul E. Freiman · Director · Chairman of the Board
  • William E. Singer · Director · Vice Chairman of the Board

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Katalyst Securities LLC (CRD 112494) · New York, New YorkSold in AL, AZ, CA, CO, CT, DC, DE, FL, GA, IA, ID, IL, IN, KS, KY, LA, MA, MD, ME, MI, MN, MO, MS, NC, ND, NJ, NV, NY, OH, OK, OR, PA, RI, SC, TX, UT, VA, VT, WA, WI, WV

Remarks in the notice

  • On fees: “In addition to a cash fee, Katalyst Securities will receive warrants to purchase common stock of the Issuer. These warrants will be issued in the amounts and on terms as described in the Issuer's Form 8-K as filed with the SEC on November 19, 2015.”
  • On the use of proceeds: “Mr. Ramat, identified in Item 3 as a Related Person, is entitled to receive a stock option exercisable for 100,000 shares of the common stock of the Issuer.”

Signed by Robert Weinstein, Chief Financial Officer. Source: SEC Form D, newest notice filed Nov 24, 2015. Read the notice at the SEC.

equity, optionsSEC
Oct 2013$1 MIssued in a merger or acquisitionUnder $2 million

Neurotrope, Inc.: Private sale, Oct 2013

Investors in this round

13 investors had bought by the notice of Oct 21, 2013: 13 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 3 investors are named for Neurotrope, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$1 M of $1 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$108,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Nevada

People named in the notice

  • James New · Executive Officer, Director
  • Robert Weinstein · Executive Officer
  • William Singer · Executive Officer, Director
  • Jay M. Haft · Director
  • John Abeles · Director
  • Ralph Bean · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • EDI Financial, Inc. (CRD 15699) · Dallas, TexasSold in all US states

Remarks in the notice

  • On fees: “In addition to cash compensation of 10% from the amount sold, the broker-dealer also received 10-year warrants to purchase the number of shares of Series A Preferred Stock equal to 10% of the number of shares it sold to investors introduced by it.”

Signed by James New, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Oct 21, 2013. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Neurotrope, Inc. chose not to state its revenue in its newest notice of a funding round (Dec 2016).

    SEC Form D · Dec 2016

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Dec 2016

That is all the official record says: Neurotrope, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

3 named in official filings. Open an investor to see everything it has backed.

Investors in Neurotrope, Inc.
InvestorKindAmountRoundRoleSource
Jay M. HaftPersonnot statednot statedHeld Series A preferred stock, director (Form 3, 2014)SEC Form 3
Northlea Partners LTDFund or asset managernot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Susanne WilkePersonnot statednot statedHeld Series B preferred stock, director (Form 3, 2016)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 221 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Neurotrope, Inc.
NameRoleNamed in
Dan AlkonExecutive officerDec 2016
Robert WeinsteinExecutive officerDec 2016
Susanne WilkeExecutive officerDec 2016
Charles S. RamatExecutive officerNov 2015
Robert S. WeinsteinExecutive officerNov 2015
James NewExecutive officerOct 2013
William SingerExecutive officerOct 2013
Bruce BernsteinDirectorDec 2016
James GottliebDirectorDec 2016
Joshua SilvermanDirectorDec 2016
Kenneth GorelickDirectorDec 2016
Shana PharesDirectorDec 2016
Susanne WilkeDirectorDec 2016
William SingerDirectorDec 2016
Charles S. RamatDirectorNov 2015
James E. GottliebDirectorNov 2015
Jay M. HaftDirectorNov 2015
Larry D. Altstiel, MDDirectorNov 2015
Paul E. FreimanChairman of the BoardNov 2015
William E. SingerVice Chairman of the BoardNov 2015
James NewDirectorOct 2013
John AbelesDirectorOct 2013
Ralph BeanDirectorOct 2013